

# BloodPAC Data Commons for Liquid Biopsy Data

Robert L. Grossman, PhD<sup>1,2</sup>; Jonathan R. Dry, PhD<sup>3</sup>; Sean E. Hanlon, PhD<sup>4</sup>; Donald J. Johann, MD<sup>5</sup>; Anand Kolatkar, PhD<sup>6</sup>; Jerry S. H. Lee, PhD<sup>7</sup>; Christopher Meyer, PhD<sup>1</sup>; Lea Salvatore, MPH<sup>2</sup>; Walt Wells, MS<sup>1,8</sup>; and Lauren Leiman, MS<sup>9</sup>

**PURPOSE** The Blood Profiling Atlas in Cancer (BloodPAC) Data Commons (BPDC) is being developed and is operated by the public-private BloodPAC Consortium to support the liquid biopsy community. It is an interoperable data commons with the ultimate aim of serving as a recognized source of valid scientific evidence for liquid biopsy assays for industry, academia, and standards and regulatory stakeholders.

**METHODS** The BPDC is implemented using the open source Gen3 data commons platform (<https://gen3.org>). In particular, the BPDC Data Exploration Portal, BPDC Data Submission Portal, the BPDC Workspace Hub, and the BloodPAC application programming interface (API) were all automatically generated from the BloodPAC Data Model using the Gen3 data commons platform. BPDC uses Gen3's implementation of the data commons framework services so that it can interoperate through secure, compliant APIs with other data commons using data commons framework service, such as National Cancer Institute's Cancer Research Data Commons.

**RESULTS** The BPDC contains 57 studies and projects spanning more than 4,100 cases. This amounts to 5,700 aliquots (blood plasma, serum, or a contrived sample) that have been subjected to a liquid biopsy assay, quantified, and then contributed by members of the BloodPAC Consortium. In all, there are more than 31,000 files in the commons as of December 2020. We describe the BPDC, the data it manages, the process that the BloodPAC Consortium used to develop it, and some of the applications that have been developed using its API.

**CONCLUSION** The BPDC has been the data platform used by BloodPAC during the past 4 years to manage the data for the consortium and to provide workspaces for its working groups.

JCO Clin Cancer Inform 5:479-486. © 2021 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License 

## INTRODUCTION

The science and applications concerning liquid biopsies are emerging and rapidly evolving. In this paper, a liquid biopsy is defined as the analysis of cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), extracellular vesicles, and/or circulating tumor cells (CTCs) that are obtained by minimally invasive routine blood draws. For many years, the concept of the liquid biopsy has been considered the holy grail of medical oncology. This is due to the many immediate clinical applications and the speed and safety compared with traditional tissue-based biopsy methods (see, for example, Table 1 in Aggarwal et al<sup>1</sup>). One of the challenges with liquid biopsy technologies is the need to capture, manage, and harmonize large amounts of digital genomic, molecular, and cellular data and the associated clinical data. Thus, there is a need for a data commons to address these challenges and to become a hub of a learning and evolving cancer data ecosystem that supports basic, regulatory, and clinical research endeavors.

A data commons co-locates (1) data, (2) cloud-based storage and computing infrastructure, and (3) commonly used software services, applications, and workspaces to create a resource for a community.<sup>2</sup> In 2017, a public-private partnership called the Blood Profiling Atlas in Cancer (BloodPAC) Consortium launched a data commons called the BloodPAC Data Commons (BPDC) to support the greater scientific research, regulatory, and clinical communities in developing liquid biopsy assays with the goal and mandate to improve outcomes for patients with cancer.<sup>3</sup> In this article, we describe the BPDC, the process that the BloodPAC Consortium used to develop BPDC, and some of the applications that have been developed over BPDC.

The BloodPAC Consortium was started to address a number of issues related to liquid biopsies, including furthering the generation of evidence to bring liquid biopsy into routine clinical practice. BloodPAC is organized into working groups that address questions such as what are the minimum data elements required

## ASSOCIATED CONTENT

### Appendix

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on March 16, 2021 and published at [ascopubs.org/journal/cci](https://ascopubs.org/journal/cci) on April 30, 2021; DOI <https://doi.org/10.1200/CCI.20.00179>

## CONTEXT

### Key Objective

To develop a data commons to support the activities and aims of the Blood Profiling Atlas in Cancer (BloodPAC) Consortium, a public-private partnership whose goal is to accelerate the development, validation, and clinical use of liquid biopsy assays to improve patient outcomes for patients with cancer.

### Knowledge Generated

By harmonizing disparate data contributed by BloodPAC stakeholders to a consensus data model and framework, the BloodPAC Consortium has leveraged the BloodPAC Data Commons and published (1) recommended preanalytic technical data elements and (2) a generic protocol for designing analytical validation studies of next-generation sequencing–based circulating tumor DNA assays.

### Relevance

The BloodPAC Data Commons has laid the initial foundation to serve as one of the sources of valid scientific evidence to advance the field of liquid biopsies and its applications to improving cancer outcomes.

when liquid biopsy data are collected, what are analytical validation protocols for developers or manufacturers of next-generation sequencing–based ctDNA diagnostic tests, and what is the concordance between liquid and solid biopsies? The first two questions were addressed by BloodPAC Working Groups and resulted in consensus recommendations, summarized by a BloodPAC technical publication.<sup>4,5</sup> The third question is being addressed by BloodPAC's Project Exhale, which is currently collecting relevant data from BloodPAC members.

The BPDC<sup>6</sup> consists of several connected components: (1) the BPDC Governance Structure that includes agreements

for contributing, accessing, and analyzing data in the BPDC; (2) the BPDC platform itself that includes an API that supports BloodPAC and third-party applications; (3) the BloodPAC Data Model (Fig 1) that describes data managed by the platform; (4) data that are contributed and managed by the commons; and (5) applications that are built over the commons that accesses data from the commons using the BPDC API and associated BPDC services. This paper describes components (2), (3), (4), and (5). BloodPAC uses the Open Commons Consortium (OCC) Data and Commons Governance Framework for (1).<sup>7</sup>

Category	Term	Description	JSON	TSV
Analysis	Alignment Workflow	A description of the specific bioinformatics workflow or pipeline used for sequence alignment.	JSON	TSV
	Molecular Tagging Workflow	A description of the specific bioinformatics workflow or pipeline used for molecular tagging of sequenced reads.	JSON	TSV
	Variant Calling Workflow	A description of the specific bioinformatics workflow or pipeline used for variant calling.	JSON	TSV
Biospecimen	Alliquot	Pertaining to a portion of the whole; any one of two or more samples of something, of the same volume or weight.	JSON	TSV
	Analyte	Any aspect of an aliquot used in an analysis or assay to characterize the sample. These aspects range from molecules, such as DNA and RNA, that can be extracted from the aliquot to general descriptions of the aliquot's components, such as cell count and morphology.	JSON	TSV
	Biospecimen	Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products. In the case of contrived samples, it describes any material obtained from a normal donor. Link this record to the followup node in order to record patient context variables related to blood draws or biospecimen collection.	JSON	TSV
	Contrived Expectation	Any mutations or other values for a particular sample that are expected to be observed through experimentation. These expectations can arise from using a cell line or other gold standard with a known set of variants.	JSON	TSV
	Read Group	Sequencing reads from one lane of an NGS experiment.	JSON	TSV
	Sample	Any part of the biological whole of the biospecimen. In the case of solid tissue, this would be a particular set of cells. In the case of fluids, such as blood, this can refer to the plasma, peripheral blood components, or any combination therein.	JSON	TSV
	Data File	Cell image	Data file containing image of a single cell from a slide.	JSON
Fragment Analyzer Trace		Data file containing the fragment analyzer or bioanalyzer trace for QC of DNA extraction, library building, quantification assay, etc.	JSON	TSV

**FIG 1.** The BloodPAC Data Commons data model. BloodPAC, Blood Profiling Atlas in Cancer; UAMS, University of Arkansas Medical Sciences; USC, University of Southern California.

**RESULTS**

**BloodPAC Data**

The BPDC contains 57 studies and projects spanning more than 4,100 cases. This amounts to 5,700 aliquots (blood plasma, serum, or a contrived sample) that have been subjected to a liquid biopsy assay, quantified, and then contributed by members of the BloodPAC Consortium. In all, there are more than 31,000 files in the commons as of December 2020.

The BPDC hosts data sets from a variety of assay types that are used for different purposes. Each type of assay is represented in the commons as a separate table, including immunoassays, sequencing assays, polymerase chain reaction assays, quantification assays, and mass cytometry assays. Each of these tables include experimental metadata to facilitate finding and subsetting data across individual data sets. Users can use these metadata elements to perform faceted search of data sets, patients, and files and download the tables for their selected cohorts.

Data contributors are required to submit experimental metadata on the instruments and platforms used for assays. Data contributors are encouraged but not required to submit accompanying metadata for library preparation kit, target capture kit, and assay kit names, vendors, and versions. These data are largely provided where relevant.

Data contributors are encouraged to provide both raw and processed data so that future analyses can reprocess the raw data using novel techniques or pipelines. For example, among the contributed 2,625 submitted somatic mutation variant call format files, 64% have corresponding

unaligned reads files (FASTQ), aligned reads files, or both.


**BloodPAC Data Model**

The data for all the studies are curated using a common data model (BloodPAC Data Model). The current version is 0.7.5, which is the 38th release of the model. Liquid biopsy data beyond genomic sequencing (eg, CTCs and extra-cellular vesicles) have been added to the model since its inception. The current data model is a graph-based data model with 44 nodes, 72 edges, and more than 380 attributes. The data model can be visualized and explored using the BPDC portal as shown in Figure 2.


Working iteratively for over a year, a BloodPAC working group developed minimum technical data elements (MTDEs) that are required for any future cfDNA data that are accepted by the BPDC<sup>4</sup> after January 1, 2018.

**BPDC Platform**

The BPDC is based upon the Gen3 Data Commons platform<sup>8</sup> that was developed by the Center for Translational Data Science at the University of Chicago and includes (1) a Data Exploration Portal that supports interactive exploration of the data and the creation of synthetic cohorts; (2) a Data Submission Portal and data submission API; (3) virtual machine-based workspaces, container-based workspaces, and Jupyter notebook-based workspaces for exploring the data, including virtual cohorts created using (1); (4) a Data Dictionary that supports graphical and tabular views; and (5) a portal for managing user security credentials to access the workspaces (3). A view of the BloodPAC Data Exploration portal is shown in Figure 2.



**FIG 2.** The BloodPAC Data Commons portal. BloodPAC, Blood Profiling Atlas in Cancer.



**FIG 3.** The figure shows how applications can be built over the BloodPAC Data Commons API. The heatmap and plots described for application 3 can be seen at the top right of this image highlighted by the dashed rectangle. BloodPAC, Blood Profiling Atlas in Cancer; MTDE, minimum technical data elements; UAMS, University of Arkansas Medical Sciences; USC, University of Southern California.

### BPDC Applications

In this section, we describe three applications that have been built over the BPDC to illustrate the types of applications that are possible using the BPDC API. As background, a primary aim of the BPDC is to provide the cancer research community with a data platform that facilitates data sharing and accelerates liquid biopsy assay research and development. As mentioned above, the BloodPAC Consortium developed preanalytical MTDEs that are required for all cfDNA data that are submitted to the BPDC.<sup>4</sup> The three applications described below all use the MTDEs.

**Application 1.** The first application accessed the pre-analytical MTDE data from the commons and clustered them to visualize the similarity, or lack of similarity, of the MTDE data across the data from the various projects submitted to the BPDC. The counts data for each pre-analytical MTDE were pulled for each project and aggregated to create a matrix of counts. Since the counts matrix was sparse and since there was a high variance in count magnitude between projects, the counts were transformed into binary attributes, with a 1 for those elements that were  $\geq 1$  and 0 otherwise. Using the binary count matrix, the Jaccard measure was computed to create a distance

matrix. That distance matrix was then run through a k-means clustering algorithm to create a heatmap, indicating which projects had the most similar preanalytical MTDE submissions. Figure 3 in the middle shows the heatmap. The source code for this example can be found in Ref. 9. This application was developed by the OCC, one of the BloodPAC members.

**Application 2.** The second application illustrates how the BPDC can be used to perform custom ad hoc queries over the data it hosts. This application was also used as a quality check of the standard operating procedure (SOP) to submit and process data since the results of the analysis were compared with the results of the analysis done locally by the BloodPAC member that contributed the data. After an authenticated login into the BPDC, a virtual machine was launched and a Jupyter notebook was created. Using the preanalytical MTDEs<sup>4</sup> and a GraphQL query executed through Python, a test set of eight patients were identified and DNA panel data and RNA-seq data associated with the patients were accessed and copied to the virtual machine. Pysam, a Python wrapper for SAMtools,<sup>10</sup> was then used to access specific gene mutations from the variant call format (VCF) files. The results matched a similar analysis done locally on the original data set. A SQLite database was then

created within the BPDC and loaded with the VCF data from the BPDC. The database was about 1 MB in size. Queries to the database to find patients with specific mutations of interest (eg, *MUC16*) were compared with those done locally on an internal database. Again, the results were identical, and response time was comparable. This application was developed by the University of Arkansas Medical Sciences, one of the BloodPAC members. Source code for this example can be found in Ref. 11.

**Application 3.** Application 3 was developed by the University of Southern California, another BloodPAC Member. In a previously published manuscript,<sup>12</sup> they analyzed the effect of preanalytical variables (eg, time to analysis) on the enumeration of rare cells in blood. The data for this study were contributed to the BPDC. This application queried the BPDC to produce a plot showing the available multianalyte experimental results from a set of patient samples. The rare cell enumeration, genomics, and proteomics data available per patient sample in the BPDC are shown as a green heatmap at the top right of Figure 3. In addition, a Jupyter Notebook in a BPDC workspace was used to recreate a rare cell enumeration plot of patient samples processed at the 24 versus 48 hour time-to-analysis time points using the preanalytical MTDE of Maximum Time to Fractionation. The plot produced can be seen at the top right of Figure 3 to the right of the heatmap. The plot of the CTC enumeration for the matched 24- and 48-hour patient blood samples generated by a query against the BPDC matched closely the same plot previously produced for the publication.<sup>12</sup> This application demonstrated that it is possible to regenerate plots using the data commons that is similar to the ones produced previously by the research team in their own lab. This is important not only to demonstrate that effective querying is available for the data in the commons, but also that others in the scientific community can perform the same analysis described in manuscripts using the BPDC. The Jupyter notebooks containing the python source code for these examples can be found in Ref. 13.

## METHODS

### Setting Up the BPDC

The BPDC is implemented using the open source Gen3 data commons platform.<sup>8</sup> In particular, the BPDC Data Exploration Portal, BPDC Data Submission Portal, the BPDC Workspace Hub, and the BloodPAC API were all automatically generated from the BloodPAC Data Model using the Gen3 data commons platform. BPDC uses Gen3's implementation of the data commons framework services<sup>2</sup> so that it can interoperate through secure, compliant APIs with other data commons using data commons framework service, such as National Cancer Institute's Cancer Research Data Commons.<sup>14</sup>

The process used to set up the BPDC consisted of the following steps:

1. BloodPAC agreed to a set of data and commons governance documents for submitting data to the commons, accessing data from the commons, and analyzing data in the commons. BloodPAC used the Data Commons Governance Framework developed by the not-for-profit OCC.
2. BloodPAC developed a set of research questions that were precompetitive and important to its members to provide a focus for the development of the BPDC.
3. BloodPAC set up a working group to develop a data model for data uploaded and managed by the Commons.
4. BloodPAC set up a working group to establish MTDEs for data submitted to the BPDC.
5. BloodPAC organized a set of what it called *data trains*, so that data could be uploaded to the BPDC, whereas (2), (3), and (4) were iteratively refined.
6. Data sets contributed to BloodPAC were organized around specific scientific questions. Several BloodPAC members developed Jupyter notebooks and simple applications over the BPDC API that analyzed the data in the BPDC and produced figures that were suitable for publication showing the results of their analysis. This demonstrated the value of the BPDC to the broader BloodPAC membership and the importance of contributing data to it.

### Development of the BloodPAC Data Model

As mentioned, data were imported into the BPDC iteratively in stages called data trains. In Data Train 1, BloodPAC came to an initial consensus about the minimum preanalytical data fields required and the importance of carefully defining these fields, making sure that all data submissions included all of them. These came to be known as the preanalytical MTDEs. Later, data trains were required to use the MTDEs, and an effort was made to go back and obtain the MTDEs for those data sets that did not have them.

The BPDC data dictionary was originally developed using the core clinical and biospecimen nodes from the Genomic Data Commons (GDC) dictionary.<sup>15</sup> Although most of the first nodes and properties were identical to the GDC dictionary, the data model was extended to include blood biopsy-specific nodes and properties. Small changes were made in the first few months to allow users to submit their data as part of Data Train 1. The original BPDC dictionary was used for about 6 months before receiving a substantial reorganization of nodes and properties based upon the experience from uploading data in Data Train 1. A major release of the data dictionary was developed and used for Data Train 2. The key changes were related to the simplification of the biospecimen tree and expansion of data file nodes. Since the move to the second version, the changes to the data dictionary have mirrored those from the first few months—small changes and additions to allow users to submit their data. Some of the changes include more detailed blood biopsy-specific clinical data achieved



through changes to the links and properties on the clinical nodes, new workflow nodes to detail analytical validation, and other processing done on data files. The data dictionary is open access and is available in Ref. 16.

### Governance Structure

The BPDC governance structure is based upon the OCC governance structures, policies, and agreements. BloodPAC and the OCC are part of the same 501(c)(3) not for profit. The OCC principles, policies, and agreements are all available in Ref. 17, including consortium membership agreements, data contributors agreements, data access agreements, security and compliance agreements, intellectual property agreements, and publication policies. BloodPAC's versions of these agreements are very similar and can be downloaded from the BloodPAC website or requested by contacting info@bloodpac.org.

As mentioned above, the BPDC is based upon the Gen3 data platform. It is operated by the Commons Services Operations Center at the Center for Translational Data Science at the University of Chicago. The Gen3 data platform and associated Commons Services Operations Center SOPs follow the policies, procedures, and controls for a Moderate system as described in NIST SP 800-53. In addition, there are periodic independent assessments by a third party and a yearly penetration test by a third party. All data submitted to the BPDC are deidentified and so are not human subject data and regulated by Health Insurance Portability and Accountability Act.

Data are submitted to the BPDC using the BloodPAC Data Contributors agreements, which require patient consent be obtained or an appropriate process (such as a one-time waiver of consent by the institutional review board) be used instead. It is the responsibility of the data contributor to obtain the required patient consents. If the BPDC is informed by the Data Contributor of withdrawn data, then the BPDC will remove the data, but not always its inclusion in already published data or aggregated data.

### Sustainability

The current sustainability model for the BloodPAC Commons is for members through member contributions to

support the core operations, including data storage, of the BPDC, and for users accessing the data via workspaces to pay for their workspaces and the associated computing costs. Finally, liquid biopsy data hosted for the public are chosen to balance the significance and importance of the data with their size, since by accepting the data, the BPDC assumes a long-term responsibility for hosting the data.

### DISCUSSION

Liquid biopsies bring a promise of improved care for patients with cancer and are now beginning to produce a disruptive change regarding clinical oncology, patient management, and the design of cancer therapeutics. Per the 21st Century Cures Act, innovative clinical trials are integral for biomarker and drug development.<sup>18</sup> The FDA Oncology Center of Excellence has highlighted the importance and pursuit of novel clinical trial designs incorporating blood-based biomarkers such as ctDNA in their recent annual report.<sup>19</sup> But the continuous validation, deployment, translation, and contextualization of the challenging digital data streams germane to the liquid biopsy may all be met and streamlined by the fruits of a robust BPDC.

The BPDC can be viewed as a publicly accessible database that contains valid scientific evidence about certain questions of interest to the liquid biopsy community (compare ref. 20). BloodPAC is developing SOPs and protocols that describe how data in the BPDC are collected, processed, curated, and evaluated. For BloodPAC studies, the BPDC captures sufficient metadata and has in place data quality and other controls so that the data products produced for the studies are reproducible and sufficiently documented so that they could be in principle reproduced by third parties.

BloodPAC is operated using policies, procedures, and controls that are designed to protect the confidentiality, integrity, and availability of the submitted data. Although data in the BPDC are deidentified, the security, privacy policies and controls that BloodPAC uses are designed to protect sensitive data, such as data containing protected health information.

### AFFILIATIONS

<sup>1</sup>Center for Translational Data Science, University of Chicago, Chicago, IL

<sup>2</sup>Open Commons Consortium, Chicago, IL

<sup>3</sup>Tempus Labs, Chicago, IL

<sup>4</sup>National Cancer Institute, Bethesda, MD

<sup>5</sup>University of Arkansas for Medical Sciences, Little Rock, AR

<sup>6</sup>Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA

<sup>7</sup>Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA

<sup>8</sup>Progressive Insurance, Cleveland, OH

<sup>9</sup>BloodPAC Consortium, Chicago, IL

### CORRESPONDING AUTHOR

Robert L. Grossman, PhD; Center for Translational Data Science, University of Chicago, 5454 S. Shore Drive, Chicago IL 60615; e-mail: robert.grossman@uchicago.edu.

### PREPRINT VERSION

Preprint version available on BIORXIV/2020/380287.

### DISCLAIMER

This article reflects the views of the authors and should not be construed to represent policies of the FDA or National Cancer Institute.

## SUPPORT

Supported by the BloodPAC Consortium and its members as well as the National Cancer Institute (Grant No. HHSN261200800001E, contract agreements 12XS527 and 15X003).

## AUTHOR CONTRIBUTIONS

**Conception and design:** Robert L. Grossman, Jonathan R. Dry, Sean E. Hanlon, Donald Johann, Jerry S. H. Lee, Lea Salvatore, Lauren Leiman

**Administrative support:** Christopher Meyer, Lea Salvatore

**Collection and assembly of data:** Robert L. Grossman, Anand Kolatkar, Christopher Meyer, Lea Salvatore

**Data analysis and interpretation:** Robert L. Grossman, Anand Kolatkar, Jerry S. H. Lee, Walt Wells

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/cci/author-center](http://ascopubs.org/cci/author-center).

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](http://Open Payments)).

### Robert L. Grossman

**Stock and Other Ownership Interests:** Tempus, HealthSeq  
**Research Funding:** Abbvie

### Jonathan R. Dry

**Employment:** Tempus, AstraZeneca  
**Stock and Other Ownership Interests:** AstraZeneca, Tempus

### Anand Kolatkar

**Stock and Other Ownership Interests:** Epic Sciences  
**Patents, Royalties, Other Intellectual Property:** HD-SCA technology was developed by myself and members of my team while at The Scripps Research Institute, which has subsequently licensed the technology to Epic Sciences for exclusive commercial development

### Jerry S. H. Lee

**Consulting or Advisory Role:** AtlasXomics Inc

### Lauren Leiman

**Stock and Other Ownership Interests:** Exact Sciences, Illumina, InVita, Starr Surgical, Lilly

No other potential conflicts of interest were reported.

## ACKNOWLEDGMENT

The authors would like to acknowledge the contributions to the BloodPAC Project from Julia Beaver, Gideon Blumenthal, Soma Ghosh, Anand Pathak, Reena Philip, and Julie Schneider from the US Food and Drug Administration as well as the figure design by Kylie Trettner from the University of Southern California. We would also like to acknowledge the BloodPAC Executive Committee and Scientific Co-Chairs as well as all BloodPAC Consortium collaborators (see [Appendix](#)).

## REFERENCES

- Aggarwal C, Rolfo CD, Oxnard GR, et al: Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. *Nat Rev Clin Oncol* 18:56-62, 2021
- Grossman RL: Data lakes, clouds, and commons: A review of platforms for analyzing and sharing genomic data. *Trends Genet* 35:223-234, 2019
- Grossman RL, Abel B, Angiuoli S, et al: Collaborating to compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium. *Clin Pharmacol Ther* 101:589-592, 2017
- Febbo PG, Martin A-M, Scher HI, et al: Minimum technical data elements for liquid biopsy data submitted to public databases. *Clin Pharmacol Ther* 107:730-734, 2020
- Godsey JH, Silvestro A, Barrett JC, et al: Generic protocols for the analytical validation of next-generation sequencing-based ctDNA assays: A joint consensus recommendation of the BloodPAC's analytical variables working group. *Clin Chem* 66:1156-1166, 2020
- BloodPAC, Blood Profiling Atlas in Cancer, <https://bloodpac.org>
- Open Commons Consortium: Commons Governance. <https://www.occ-data.org/commons-governance>
- Gen3 Data Platform, <https://gen3.org>
- BloodPAC - MTDEs: Similarity Analysis, <https://github.com/occ-data/bpa-mtde.similarity>
- Li H, Handsaker B, Wysoker A, et al: The sequence alignment/map format and SAMtools. *Bioinformatics* 25:2078-2079, 2009
- BloodPAC Data Commons, Community Notebooks, [https://github.com/occ-data/bpa-functions/tree/master/Community\\_Notebooks/UAMS](https://github.com/occ-data/bpa-functions/tree/master/Community_Notebooks/UAMS)
- Rodríguez-Lee M, Kolatkar A, McCormick M, et al: Effect of blood collection tube type and time to processing on the enumeration and high-content characterization of circulating tumor cells using the high-definition single-cell assay. *Arch Pathol Lab Med* 142:198-207, 2018
- BloodPAC Data Commons, Community Notebooks, [https://github.com/occ-data/bpa-functions/tree/master/Community\\_Notebooks/USC](https://github.com/occ-data/bpa-functions/tree/master/Community_Notebooks/USC)
- Hinkson IV, Davidsen TM, Klemm JD, et al: A comprehensive infrastructure for big data in cancer research: Accelerating cancer research and precision medicine. *Front Cell Dev Biol* 5:83, 2017
- Grossman RL, Heath AP, Ferretti V, et al: Toward a shared vision for cancer genomic data. *N Engl J Med* 375:1109-1112, 2016
- BloodPAC Data Commons, Data Dictionary, <https://data.bloodpac.org/DD>
- Open Commons Consortium, <https://www.occ-data.org/>
- Hudson KL, Collins FS: The 21st Century Cures Act—A view from the NIH. *N Engl J Med* 376:111-113, 2017
- The Office of Commissioner: OCE Annual Report. FDA, 2020. <https://www.fda.gov/about-fda/oncology-center-excellence/oce-annual-report>
- Center for Devices and Radiological Health: Use of Public Human Genetic Variant Databases to Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics. US Food and Drug Administration, 2019. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-public-human-genetic-variant-databases-support-clinical-validity-genetic-and-genomic-based-vitro>



## APPENDIX BLOODPAC EXECUTIVE COMMITTEE AND SCIENTIFIC CO-CHAIRS

### Executive Committee

Philip G. Febbo—Senior Vice President and Chief Medical Officer, Illumina

Robert L. Grossman—Professor, University of Chicago CTDS and Founder/Director, Open Commons Consortium

Peter Kuhn—Professor, University of Southern California

Anne-Marie Martin—Senior Vice President, Global Head, Experimental Medicine Unit, GSK

Jake Vinson—Chief Executive Officer, Prostate Cancer Clinical Trials Consortium

### Scientific Co-Chairs

Kelli Bramlett—Director of R&D, Thermo Fisher Scientific

Darya Chudova—Senior Vice President, Technology, Guardant Health

James H. Godsey—VP, Assay Development, Illumina

Jerry S. H. Lee—Chief Science and Innovation Officer, Lawrence J. Ellison Institute for Transformative Medicine of University of Southern California

Hakan Sakul—VP and Head of Diagnostics, Pfizer

Howard I. Scher—Physician and Head, Biomarker Development Initiative at Memorial Sloan Kettering Cancer Center

Jennifer Dickey, Vice President, Regulatory and Quality, Personal Genome Diagnostics

### BloodPAC Consortium Collaborators

1. American Association for Cancer Research (AACR)
2. American Cancer Society (ACS)
3. Association for Molecular Pathology
4. AstraZeneca
5. Bio-Rad Laboratories
6. Breast Cancer Research Foundation (BCRF)
7. Bristol-Myers Squibb
8. Center for Translational Data Science at the University of Chicago
9. Center for Genetic Medicine Research at Children's National Medical Center
10. Ceres Nanosciences
11. Chan Soon-Shiong Institute of Molecular Medicine at Windber
12. College of American Pathologists
13. Eli Lilly and Company
14. Epic Sciences
15. Fluxion Biosciences
16. Focused Ultrasound Foundation
17. Foundation for the National Institutes of Health
18. Foundation Medicine, Inc
19. Freenome
20. Friends of Cancer Research
21. GlaxoSmithKline
22. Guardant Health
23. Horizon Discovery Ltd
24. Illumina, Inc
25. Inivata
26. LGC/Seracare
27. Memorial Sloan Kettering Cancer Center (MSKCC)
28. Movember Foundation
29. National Cancer Institute at the National Institutes of Health (NIH/NCI)
30. Novartis
31. Open Commons Consortium (OCC)
32. Personal Genome Diagnostics (PGDx)
33. Pfizer, Inc
34. Prostate Cancer Foundation (PCF)
35. SolveBio
36. Streck
37. Sysmex Inostics
38. Tempus Labs
39. The Arkansas Bioinformatics Consortium (AR-BIC)/University of Arkansas
40. The Prostate Cancer Clinical Trials Consortium (PCCTC)
41. Thermo Fisher Scientific
42. University of Southern California
43. US Department of Defense (DOD)
44. US Department of Veteran's Affairs (VA)
45. US Food and Drug Administration (FDA)